Triple Play BioPharma Company: Sunshine Biopharma (Stock Symbol: SBFM) in High Value Sectors of Cancer Treatments, Science-Based Supplements and a Key Anti-Coronavirus Drug

January 14, 2021 (Viz Release) – – Triple Play BioPharma Company: Sunshine Biopharma (Stock Symbol: SBFM)

Sunshine Biopharma SBFM

– BioPharma Company with Worldwide Patents on Effective Cancer Drugs.
– Joint Agreement to Advance Cancer Treatment to Clinical Trials in Canada.
– Covid Treatment Expected to be Effective Against New Virus Variants.
– Convertible Notes Paid Off Preventing New Shares Reaching Market.
– $2,000,000 + Financing for Coronavirus Treatment Program.
– New Distribution of Nutritional Supplements in Asia and the Far East.

Sunshine Biopharma (OTC: SBFM) is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, SBFM is engaged in the development and commercialization of science-based nutritional supplements and is also currently engaged in the development of a new pharmaceutical to treat infections of the Covid-19 Coronavirus.

Triple Play BioPharma Company: Sunshine Biopharma (Stock Symbol: SBFM) in High Value Sectors of Cancer Treatments, Science-Based Supplements and a Key Anti-Coronavirus Drug

Since inception, SBFM has been involved in the development of Adva-27a, a small molecule that has been shown to be exceptionally effective at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5). SBFM is a direct owner of all worldwide patents covering Adva-27a, including all issued and pending patents.

– SBFM Coronavirus Treatment Anticipated to Be Effective Against the New Variant Identified in the UK

BioPharma Company: Sunshine Biopharma (Stock Symbol: SBFM) in High Value Sectors of Cancer Treatments, Science-Based Supplements and a Key Anti-Coronavirus Drug
On December 22nd SBFM announced that its Anti-Coronavirus drug development program is unaffected by the recent discovery of a new strain of Coronavirus in Southern England. The new strain appears to be more easily transmissible due to a mutation in the Spike Protein, the crown-like structure on the surface of the virus which allows it to gain entry into the host cell.

The SBFM Anti-Coronavirus compound, SBFM-PL4, acts on the Coronavirus Papain-Like Protease (PLpro) which is a non-structural protein encoded by the viral genome and synthesized by the hijacked protein synthesis machinery of the host cell. SBFM-PL4 inhibits PLpro and arrests viral replication. SBFM-PL4 is expected to inhibit the PLpro of the UK variant just as well as it does the original strain since the UK strain does not show any mutations in the PLpro gene.

– New Batch of Adva-27a for Testing on TOPII Amplified Cancers

On December 8th SBFM announced that it has ordered a new batch of Adva-27a from its manufacturer in China. The material will be delivered to the laboratories of the SBFM drug development partner in Montreal (Canada). SBFM plans to use the material to conduct testing on various types of cancer cells that overproduce Topoisomerase II (TopII). Following these cell culture studies, SBFM will proceed to performing studies on mice harboring tumors of human origin with TopII amplification. TopII is an essential cell cycle enzyme that is amplified in approximately 4% of all human cancers.  All cancer types that have amplification of the Topoisomerase II gene are potential new targets for the SBFM Adva-27a. This is an additional application for Adva-27a beyond the original multidrug resistance indication.

BioPharma Company: Sunshine Biopharma Key Anti-Coronavirus Drug

– SBFM Pays Off Convertible Notes in Cash Preventing New Shares from Hitting the Market

On December 3rd SBFM announced that it has paid off just over $100,000 worth of convertible notes associated with the company. The Board of Directors deemed this action to be a priority for the in order to mitigate dilutive conversions and maximize shareholder value.

– SBFM Receives Third Tranche from Previously Announced $2,000,000 + Financing for Coronavirus Treatment

On December 1st SBFM announced that it has received the third tranche of funding under a recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc. This brings the total to $800,000 that SBFM has received under this financing. The proceeds will be used for the ongoing development of the SBFM Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the company’s flagship anticancer compound targeted for pancreatic cancer.

– Agreement with a Montreal-based Company to Advance the Highly Promising Development of Adva-27a Anticancer Compound

On November 18th SBFM announced a collaboration agreement with a Montreal-based company for the purposes of advancing the development of the SBFM anticancer compound, Adva-27a. The goal of this collaboration is to develop and implement chemical synthesis procedures for Adva-27a and test the resulting material in various types of cancer cells grown in culture. Based on the cell culture results, the SBFM drug development partner will conduct mice studies in preparation for entry of Adva-27a into clinical trials. It is anticipated that the clinical trials will be for Stage IV pancreatic cancer indication and will be performed at McGill University’s Jewish General Hospital in Montreal, Canada.

Triple Play BioPharma Company: Sunshine Biopharma (Stock Symbol: SBFM) in High Value Sectors of Cancer Treatments, Science-Based Supplements and a Key Anti-Coronavirus Drug

– Distribution of High Value Essential-9(TM) in Asia and the Far East

On November 10th SBFM announced an agreement with JOAH International Pte., Ltd., headquartered in Singapore, for distribution of Essential-9tm in Asia and the Far East. The SBFM Essential-9tm is a nutritional supplement tablet comprised of a balanced formula of the 9 essential amino acids that the human body cannot make. Essential-9tm is authorized for marketing by Health Canada under NPN 80089663.

Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, chronic fatigue, weight gain, and weakened immune system. The SBFM Essential-9TM provides a balanced formula of all 9 Essential Amino Acids in free-form, ready to be absorbed. Essential-9tm is suitable for everyone: Vegans, Seniors, Dieters, Athletes, and everyone looking to increase their health. In North America, Essential-9tm is available on and

For more information on Sunshine Biopharma (SBFM) visit:

Look at SBFM’s 2 Month Chart

DISCLAIMER: (CA) is a third-party publisher and news dissemination service provider. CA is NOT affiliated in any manner with any company mentioned herein. CA is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CA’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CA has been compensated $500 by a third-party for dissemination of this Article.

Disclaimer/Safe Harbor:

These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.